Abstract
In this issue of Blood, Hegerova et al report on a study of 20 hospitalized patients with severe or critical coronavirus disease 2019 (COVID-19) who were transfused with convalescent plasma (CP); the authors suggest a favorable, albeit modest, benefit as compared with 20 matched (ie, non-transfused) controls, particularly when transfusion was undertaken within the first 7 days of hospitalization.
Original language | English (US) |
---|---|
Pages (from-to) | 654-655 |
Number of pages | 2 |
Journal | Blood |
Volume | 136 |
Issue number | 6 |
DOIs | |
State | Published - Aug 2020 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology